|PROTAC PD-1/PD-L1 degrader-1
|PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 degrader, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner.
|PD1-PDL1 inhibitor 2 is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction with IC50 of 18 nM.
|PD-1/PD-L1 Inhibitor 3 is capable of inhibiting the interaction of PD-L1 with PD-1 and with CD80.
|PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.
|PD-1-PDL1 Inhibitor C2a Hydrochloride
|PD-1-PD-L1 inhibitor C2a is a potential inhibitor of PD-1/PD-L1 interaction by inducing an enlarged interaction interface that results in the open 'face-back' tunnel through the PD-L1 dimer.
|PD-1-PDL1 Inhibitor C1a Hydrochloride
|PD-1-PD-L1 inhibitor C1a is a potential inhibitor of PD-1/PD-L1 interaction which exhibits the structures capped on one side of the channel of PD-L1 homodimer.
|PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
|BMS-1001 HCl is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 HCl exhibits low-toxicity in cells. BMS-1001 binds to human PD-L1 and blocks its interaction with PD-1.
|AUPM-170 is one of CA-170 analogues extracted from patent WO 2015033299 A1, compound example 4.